FTSE 250 movers: Genus soars on FDA green light; Mobico tanks again.

FTSE 250 (MCX) 19,755.34 -0.27%

Source: Sharecast

Animal genetics company Genus surged after the US Food and Drug Administration (FDA) approved its PRP gene edit under its PRRS Resistant Pig ("PRP") programme for use in the U.S. food supply chain.

Mobico tanked again after poor results this week.

Market Movers

FTSE 250 - Risers

Genus (GNS) 1,886.00p 18.92%
Senior (SNR) 136.40p 2.25%
Drax Group (DRX) 614.00p 2.08%
SSP Group (SSPG) 146.00p 1.88%
European Opportunities Trust (EOT) 854.00p 1.79%
Ninety One (N91) 147.40p 1.66%
Marshalls (MSLH) 279.00p 1.64%
Patria Private Equity Trust (PPET) 571.00p 1.42%
Clarkson (CKN) 3,270.00p 1.40%
Pennon Group (PNN) 499.40p 1.26%

FTSE 250 - Fallers

Mobico Group (MCG) 28.94p -9.45%
PPHE Hotel Group Ltd (PPH) 1,260.00p -5.26%
Carnival (CCL) 1,207.50p -4.13%
IP Group (IPO) 42.10p -3.88%
Dr. Martens (DOCS) 54.35p -3.55%
Aston Martin Lagonda Global Holdings (AML) 67.60p -3.29%
THG (THG) 24.50p -2.93%
Syncona Limited NPV (SYNC) 90.70p -2.68%
Wizz Air Holdings (WIZZ) 1,627.00p -2.52%
BH Macro Ltd. GBP Shares (BHMG) 391.50p -2.37%

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.